Posted from: Tuesday, October 07, 2014 - 05:13 PM - Present

Keytruda Aproved for Advanced Melanoma

September 4, 2014 – Keytruda (pembrolizumab), manufactured by Merck, was approved by the U.S. Food and Drug Administration (FDA) for the breakthrough therapy to treat patients with with unresectable or metastatic melanoma.

Keytruda is indicated to be administered in 2mg/kg by intravenous infusion every three weeks until disease progression or unacceptable toxicity.

Merck plans on launching Keytruda within one week.

 

If you have any questions you can contact our Client Services Call Center at 1-877-723-6005.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

 

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Thursday, November 23, 2017 - 10:39 AM.